Loading quotes...

Forecast

The analysts' average price target is €65.32 (+4.60%). The median is €68.56 (+9.78%).

Buy
  14
Hold
  10
Sell
  2

  • Alcon acquires Neurotech for $550 million and bolsters retina business with Encelto

    Alcon has acquired Neurotech Pharmaceuticals for $550 million and may make additional success‑based payments. The deal adds Encelto to its retina portfolio — the only therapy approved in the U.S. for MacTel type 2 — addressing around 25,000 diagnosed patients in the U.S. Neurotech brings encapsulated cell therapies for chronic and neurodegenerative eye diseases. Alcon expects slight revenue growth in 2027 and a temporary hit to adjusted earnings per share, after which the acquisition is expected to be accretive. » More on finanzen.net


  • Alcon launches surgical microscope Unity M

    Alcon has introduced the modular surgical microscope “Unity M” for eye surgery, which is said to provide a more stable view through an improved red reflex zone and adjustable color illumination. The device is approved in the US, Japan, Canada, India and Europe; deliveries began in September with the market launch first in the US and Japan, and later in Europe. The stock reacted with an intraday decline of around 1 percent. » More on finanzen.net


  • Alcon places €500 million bond at 3.875% due 2033

    Alcon, through its subsidiary Alcon Finance Corporation, is issuing a five‑year €500 million bond with a 3.875% coupon. The bond will be listed on the Luxembourg Stock Exchange and traded on the Euro MTF; closing of the transaction is scheduled for 2 September. Proceeds are to be used for general corporate purposes, including wholly or partly refinancing existing debt. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Alcon has already paid €0.31 in dividends. The last payout was in May.

Financials

In the last quarter, Alcon had revenue of €2.47B and net profit of €0
(EUR) June 2026
YoY
Revenue 2.47B 12.31%
Gross profit 1.47B 24.63%
Net profit 0 100.00%
EBITDA 700.97M 35.00%

Fundamentals

Metric Value
Market capitalization
€30.4B
Number of shares
483.4M
52-week high/low
€78.54 - €55.42
Dividend yield
0.49%
Dividends TTM
€0.31
Beta
0.73
P/E ratio
53.98
PEG ratio
-1.35
P/B ratio
1.58
P/S ratio
3.14

Company profile

Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Name
Alcon
CEO
David J. Endicott
Headquarters Geneva, ge
Switzerland
Website
Sector
Health Care
Industry
Health Care Technology
IPO
04/09/2019
Employees 25,000

Ticker symbols

Exchange Symbol
NYSE
ALC
SIX
ALC.SW
DĂĽsseldorf
2U3.DU
Hamburg
2U3.HM
London
0A0D.L
MĂĽnchen
2U3.MU
🍪

Parqet  uses cookies. Learn more